Questcor's (NAS: QCOR) flagship drug, Acthar, has been around for over 60 years. Despite its age, the company discovered a way to breathe new life into sales of this old drug. So, why does this remain one of the most controversial companies in the health care space today? In this video, Motley Fool health care bureau chief Brenton Flynn takes us through some of his likes and dislikes with Questcor.
So, while Acthar is growing at a torrid pace -- and minting money in the process -- recent events have created significant doubts about Questcor's future. Will insurance companies continue to cover the drug? Will a government investigation lead to huge fines? We highlight these high-profile issues inside our brand new premium research report on Questcor. In it, you'll learn about the key opportunities and threats facing the company, as well as multiple reasons to buy and sell the stock. We're providing a full year of analyst updates as key news hits, so make sure to claim a copy today by clicking here now.
The article Questcor Pharmaceuticals: Likes and Dislikes originally appeared on Fool.com.
Brenton Flynn has no positions in the stocks mentioned above. Max Macaluso has no positions in the stocks mentioned above. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.